Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Vertex Pharmaceuticals Incorporated ... Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.

Vertex Pharmaceuticals stock declined almost 13 ... Consistent Rise in VRTX’s CF Product Sales Vertex’s cystic franchise (“CF”) sales continue to grow, driven by higher sales of Trikafta ...